Shanghai Bio-Heart Launches Iberis® RDN System in Europe

Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) has shared an update.

Shanghai Bio-Heart Biological Technology Co., Ltd. announced the completion of the first commercial procedure of its Iberis® RDN system in Germany, marking a significant milestone in its European operations. The system, which offers a safer and more effective transradial approach for renal denervation, is the only globally approved product for both transradial and transfemoral approaches. This advancement enhances the company’s market positioning and expands its reach in the cardiovascular treatment sector, potentially impacting stakeholders positively by offering a less invasive treatment option for hypertension.

More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H

Shanghai Bio-Heart Biological Technology Co., Ltd. operates in the medical technology industry, focusing on the development and commercialization of innovative cardiovascular products. The company, through its subsidiary AngioCare, has developed the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System, which is designed for renal denervation procedures. The company has a strategic partnership with Biosensors International Group to commercialize this system across various regions, including Europe, Asia-Pacific, and Latin America.

YTD Price Performance: 7.93%

Average Trading Volume: 155,758

Technical Sentiment Consensus Rating: Hold

Current Market Cap: HK$740.8M

For an in-depth examination of 2185 stock, go to TipRanks’ Stock Analysis page.